Clinical Trial Update: Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of venetoclax and azacitidine for newly diagnosed early T-cell precursor acute lymphoblastic leukemia and T-cell acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Phenotype Acute Leukemia Myeloid
• T-cell Acute Lymphoblastic Leukemia
• T-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: yuejun Liu | Conditions: Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING